Gossamer Bio, Inc. GOSS
11.23 USD -0.20 (-1.75%)
Regular-session close
11.41 +0.18 +1.60%
After hours · Nov 19, 7:38 PM ET
10.80 Day range 11.85
8.43 52-week range 303.20
- YTD
- -95.47%
- 1 year
- -95.53%
News
zacks.com Does Gossamer Bio (GOSS) Have the Potential to Rally 659.56% as Wall Street Analysts Expect? The consensus price target hints at a 659.6% upside potential for Gossamer Bio (GOSS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings…benzinga.com Gossamer Bio Files Prospectus Related To The Proposed Resale Or Other Disposition By The Selling Securityholders Of Up To 1,697,363 Shares Of Common Stock https://www.sec.gov/Archives/edgar/data/1728117/000172811726000123/a20261116-gossxresalesx3.htm
benzinga.com Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results Gossamer Bio, Inc. (NASDAQ:GOSS) on Tuesday reported mixed third-quarter financial results.
benzinga.com Gossamer Bio Analysts Slash Their Forecasts Following Q3 Results Gossamer Bio missed Q3 loss estimates but beat sales forecasts; shares fell 4.7% as analysts cut price targets following its seralutinib NDA filing.benzinga.com Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $96 Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $120 to $96.
benzinga.com Wedbush Maintains Neutral on Gossamer Bio, Lowers Price Target to $32 Wedbush analyst Laura Chico maintains Gossamer Bio (NASDAQ:GOSS) with a Neutral and lowers the price target from $80 to $32.
benzinga.com Gossamer Bio Q3 EPS $(7.36) Misses $(3.68) Estimate, Sales $38.431M Beat $12.148M Estimate Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(7.36) per share which missed the analyst consensus estimate of $(3.68) by 100 percent. This is a 3404.76 percent decrease over losses of…
businesswire.com Gossamer Bio Announces Third Quarter 2026 Financial Results and Provides Business Update SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
defenseworld.net Corient Private Wealth LP Purchases 1,647,315 Shares of Gossamer Bio, Inc. $GOSS Corient Private Wealth LP increased its position in shares of Gossamer Bio, Inc. (NASDAQ: GOSS) by 41.3% in the undefined quarter, according to its most recent disclosure with the SEC. The…
businesswire.com Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
defenseworld.net Hsbc Holdings PLC Increases Stock Position in Gossamer Bio, Inc. $GOSS Hsbc Holdings PLC boosted its holdings in Gossamer Bio, Inc. (NASDAQ: GOSS) by 1,289.4% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
businesswire.com Gossamer Bio Appoints Greg Ciongoli to Board of Directors SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment…
gurufocus.com Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmaceutical company focused on the development and commercializa
businesswire.com Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
businesswire.com Gossamer Bio Announces 1-for-80 Reverse Stock Split SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
gurufocus.com Gossamer Bio to Present at Cantor Global Healthcare Conference Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
businesswire.com Gossamer Bio to Present at Cantor Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment…
gurufocus.com Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval Gossamer Bio, Inc. (Nasdaq: GOSS) (the âCompanyâ or âGossamerâ), a clinical-stage biopharmaceutical company focused on the development and commercializa
businesswire.com Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
zacks.com Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.
businesswire.com Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
prnewswire.com Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their…
benzinga.com Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026 following a…
seekingalpha.com Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
businesswire.com Gossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
